UTHR – Market expectations are for Uniform ROA to fade, but management is positive about their manufacturing pipeline and DPI approval
- United Therapeutics Corporation (UTHR) currently trades below corporate but around historical averages relative to Uniform earnings, with an 8.0x Uniform P/E (Fwd. V/E’).
At these levels, markets are pricing in expectations for Uniform ROA to fade to 6%, accompanied by 7% Uniform asset growth.
Meanwhile, analysts expect Uniform ROA to remain at 19% levels through 2023, accompanied by 11% Uniform asset growth.
If sustained going forward, these levels would imply a stock price closer to $603, representing significant potential equity upside for the firm.
Moreover, the firm’s most recent earnings call suggests management is positive about their manufacturing pipeline and DPI approval.